Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: A randomised clinical trial

BMC Medicine

Volumn 7, Issue , 2009, Pages

  Gillet, Yves ^a   Habermehl, Pirmin ^b   Thomas, Stéphane ^c   Eymin, Cécile ^c   Fiquet, Anne ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Abteilung Neonatologie   (Germany)

^c SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; M M RVAXPRO; MEASLES MUMPS RUBELLA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; BODY TEMPERATURE MONITORING; CHICKENPOX; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MEASLES; MEASLES LIKE RASH; MULTICENTER STUDY; MUMPS; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION; BLOOD; COMPARATIVE STUDY; FRANCE; GERMANY; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, VIRAL; CHICKENPOX VACCINE; FEMALE; FRANCE; GERMANY; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MEASLES-MUMPS-RUBELLA VACCINE;

EID: 65149087165     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-7-16     Document Type: Article

References (42)

1. Gershon AA Measles virus (rubeola) Mandell, Douglas, and Bennett's Principles and Practise of Infectious Disease Oxford: Churchill Livingstone Mandell GL, Bennett JE, Dolin R 5 2000, 2:801-1809.
2. Baum SG Litman N Mumps virus Mandell, Douglas, and Bennett's Principles and Practise of Infectious Disease Oxford: Churchill Livingstone Mandell GL, Bennett JE, Dolin R 5 2000, 2:1776-1781.
3. Gershon AA Rubella virus (German measles) Mandell, Douglas, and Bennett's Principles and Practise of Infectious Disease Oxford: Churchill Livingstone Mandell GL, Bennett JE, Dolin R 5 2000, 2:1708-1714.
4. Heininger U Seward JF Varicella Lancet 2006, 368:1365-1376. 10.1016/ S0140-6736(06)69561-5 17046469
5. Zhou F Santoli J Messonnier ML Yusuf HR Shefer A Chu SY Rodewald L Harpaz R Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001 Arch Pediatr Adolesc Med 2005, 159:1136-1144. 10.1001/archpedi.159.12.1136 16330737
6. Peltola H Heinonen O Valle M Paunio M Virtanen M Karanko V Cantell K The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two-dose vaccination program New Engl J Med 1994, 331:1397-1402. 10.1056/NEJM199411243312101 7969278
7. Böttiger M Christenson B Romanus V Taranger J Strandell A Swedish experience of two-dose vaccination programme aiming at eliminating measles, mumps, and rubella Br Med J (Clin Res Ed). 1987, 295(6608):1264-1267. 10.1136/bmj.295.6608.1264 3120971 1248321
8. Centers for Disease Control and Prevention Summary of notifiable diseases, United States, 1998 MMWR Morb Mortal Wkly Rep. 1999, 47(53):2-93.
9. Jumaan AO Yu O Jackson LA Bohlke K Galil K Seward JF Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002 J Infect Dis 2005, 191:2002-2007. 10.1086/430325 15897984
10. Nguyen HQ Jumaan AO Seward JF Decline in mortality due to varicella after implementation of varicella vaccination in the United States N Engl J Med 2005, 352:450-458. 10.1056/NEJMoa042271 15689583
11. WHO Europe Eliminating measles and rubella and preventing congenital rubella infection. WHO European Region strategic plan 2005-2010 2005. http://www.euro.who.int/Document/E87772.pdf Accessed June 2008.
12. WHO Reported estimates of MCV coverage http://www.who.int/ immunization_monitoring/en/globalsummary/timeseries/tscoveragemcv.htm Accessed June 2008. 2097487
13. WHO Reported estimates of MCV coverage (2nd dose) http://www.who.int/ immunization_monitoring/en/globalsummary/timeseries/tscoveragemcv2.htm Accessed June 2008. 2097487
14. Centers for Disease Control and Prevention Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 2007, 56:1-40.
15. Rasch G Hellenbrand W Germany adds varicella vaccine to the national vaccination programme Eurosurveillance Weekly [1812-075X] 2004, 7:040729.
16. EUVAC.NET Varicella vaccination overview in European countries http://www.euvac.net/graphics/euvac/vaccination/var.html Accessed June 2008.
17. Ramet J Weil-Olivier C Sedlak W on behalf of the Confederation of the European Specialists of Paediatrics(CESP)/European Academy of Paediatrics (EAP) Is Europe ready to embrace a policy of universal varicella vaccination? Int J Clin Pract 2005, 59:1326-1333. 10.1111/ j.1742-1241.2005.00647.x 16236088
18. Sengupta N Booy R Schmitt HJ Peltola H Van-Damme P Schumacher RF Campins M Rodrigo C Heikkinen T Seward J Jumaan A Finn A Olcén P Thiry N Weil-Olivier C Breuer J Varicella vaccination in Europe: Are we ready for a universal childhood programme? Eur J Pediatr 2008, 167:47-55. doi 10.1007/s00431-007-0424-0. 10.1007/s00431-007-0424-0 17334784
19. Usonis V Bakasenas V Kaufhold A Chitour K Clemens R Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children Pediatr Infect Dis J 1999, 18:42-48. 10.1097/00006454-199901000-00011 9951979
20. Plotkin SA Orenstein WA Vaccines Philadelphia: WD Saunders 4 2004.
21. Hilleman MR Stokes J Jr Buynak EB Weibel R Halenda R Goldner H Studies of live attenuated measles virus vaccine in man: II. appraisal of efficacy Am J Public Health Nations Health. 1962, 52(2):44-56. 10.2105/ AJPH.52.Suppl_2.44 13907411 1522574
22. Wyll SA Witte JJ Measles in previously vaccinated children: An epidemiological study JAMA 1971, 216:1306-1310. 10.1001/jama.216.8.1306 5108448
23. Hilleman MR Weibel RE Buynak EB Stokes J Jr Whitman JE Jr Live, attenuated mumps-virus vaccine. 4. Protective efficacy as measured in a field evaluation N Engl J Med 1967, 276:252-258. 6016061
24. Lewis JE Chernesky MA Rawls ML Rawls WE Epidemic of mumps in a partially immune population Can Med Assoc J 1979, 121:751-754. 1704254 519614
25. Stokes J Jr Weibel RE Buynak EB Hilleman MR Protective efficacy of duck embryo rubella vaccines Pediatrics 1969, 44:217-224. 5817338
26. Landrigan PJ Stoffels MA Anderson E Witte JJ Epidemic rubella in adolescent boys: Clinical features and results of vaccination JAMA 1974, 227:1283-1287. 10.1001/jama.227.11.1283 4405976
27. European Medicines Agency. MMRVAXPRO Scientific Discussion 2006. http://www.emea.europa.eu/humandocs/PDFs/EPAR/mmrvaxpro/060406en6.pdf
28. Li S Chan ISF Matthews H Heyse JF Chan CY Kuter BJ Kaplan KM Vessey SJR Sadoff JC Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection Pediatr Infect Dis J 2002, 21:337-342. 10.1097/ 00006454-200204000-00014 12075766
29. Weibel RE Neff BJ Kuter BJ Guess HA Rothenberger CA Fitzgerald AJ Connor KA McLean AA Hilleman MR Bunyak EB Live attenuated varicella virus vaccine. Efficacy trial in healthy children N Engl J Med 1984, 310:1409-1415. 6325909
30. White CJ Kuter BJ Hildebrand CS Isganitis KL Matthews H Miller WJ Provost PJ Ellis RW Gerety RJ Calandra GB Varicella vaccine (VARIVAX) in healthy children and adolescents: Results from clinical trials, 1987 to 1989 Pediatrics 1991, 87:604-610. 1850506
31. Vázquez M LaRussa PS Gershon AA Steinberg SP Freudigman K Shapiro ED The effectiveness of the varicella vaccine in clinical practice N Engl J Med 2001, 344:955-960. 10.1056/NEJM200103293441302 11274621
32. Kuter B Matthews H Shinefield H Black S Dennehy P Watson B Reisinger K Kim LL Lupinacci L Hartzel J Chan I Study Group for Varivax Ten year follow-up of healthy children who received one or two injections of varicella vaccine Pediatr Infect Dis J 2004, 23:132-137. 10.1097/ 01.inf.0000109287.97518.67 14872179
33. Seward JF Watson BM Peterson CL Mascola L Pelosi JW Zhang JX Maupin TJ Goldman GS Tabony LJ Brodovicz KG Jumaan AO Wharton M Varicella disease after introduction of varicella vaccine in the United States, 1995-2000 JAMA 2002, 287:606-611. 10.1001/jama.287.5.606 11829699
34. The National Vaccine Advisory Committee Standards for child and adolescent immunization practices Pediatrics 2003, 112:958-963. 14523192
35. Shinefield HR Black SB Staehle BO Matthews H Adelman T Ensor K Li S Chan I Heyse J Waters M Chan CY Vessey SJ Kaplan KM Kuter BJ Kaiser Permanente Medical Team for Varivax Vaccination with measles, mumps and rubella vaccine and varicella vaccine: Safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children Pediatr Infect Dis J 2002, 21:555-561. 10.1097/00006454-200206000-00014 12182381
36. Keller PM Lonergan K Neff BJ Morton DA Ellis RW Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies J Virol Methods 1986, 14:177-188. 10.1016/ 0166-0934(86)90048-0 3021804
37. Wasmuth EH Miller WJ Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen J Med Virol. 1990, 32(3):189-193. 10.1002/jmv.1890320310 2177782
38. Provost PJ Krah DL Kuter BJ Morton DH Schofield TL Wasmuth EH White CJ Miller WJ Ellis RW Antibody assays suitable for assessing immune responses to live varicella vaccine Vaccine 1991, 9:111-116. 10.1016/ 0264-410X(91)90266-9 1647574
39. Miettinen O Nurminen M Comparative analysis of two rates Stat Med 1985, 4:213-226. 10.1002/sim.4780040211 4023479
40. Hochberg Y A sharper Bonferroni procedure for multiple tests of significance Biometrika 1988, 75:800-802. 10.1093/biomet/75.4.800
41. Dennehy PH Reisinger KS Blatter MM Veloudis BA Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children Pediatrics 1991, 88:604-607. 1881743
42. Wise RP Salive ME Braun MM Mootrey GT Seward JF Rider LG Krause PR Postlicensure safety surveillance for varicella vaccine JAMA 2000, 284:1271-1279. 10.1001/jama.284.10.1271 10979114